Matthew K. Fust
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
RARE FDA approves Fayuvi, triggers $203M voucher sale. Ultragenyx Pharmaceutical received FDA approval for its gene therapy Fayuvi. The approval was followed by a second sale of a priority review voucher, bringing in about $203 million within a week. The cash from the voucher sale adds to the company’s resources as it looks to expand its approved product portfolio. Analysts are evaluating whether the newly approved product can support the next growth phase.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
NMRA noted among top stock movers today. NMRA appeared in today's list of top stock movements, reflecting notable price activity. The stock is currently trading near its support level of $1.60 and shows a low RSI, suggesting oversold conditions. Analyst consensus target remains at $6.14, well above the current price range.
Transaction History
| ATRA | ▲ Buy | Grant | 12,000 | $0 | 6/9/2026 | View on chart |
| RARE | ▲ Buy | Grant | 7,751 | $0 | 5/14/2026 | View on chart |
| ATRA | ▲ Buy | Grant | 7,828 | $0 | 6/10/2025 | View on chart |
| RARE | ▲ Buy | Grant | 5,740 | $0 | 5/15/2025 | View on chart |
| NMRA | ▲ Buy | Option Exercise | 6,205 | $55K | 10/18/2024 | View on chart |
| NMRA | ▲ Buy | Option Exercise | 7,844 | $20K | 10/18/2024 | View on chart |
| NMRA | ▼ Sell | Open Market | 14,049 | $239K | 10/18/2024 | View on chart |
| NMRA | ▲ Buy | Option Exercise | 3,783 | $31K | 10/17/2024 | View on chart |
| NMRA | ▲ Buy | Option Exercise | 1,800 | $16K | 10/17/2024 | View on chart |
| NMRA | ▲ Buy | Option Exercise | 2,156 | $5K | 10/17/2024 | View on chart |
| NMRA | ▼ Sell | Open Market | 7,739 | $132K | 10/17/2024 | View on chart |
| RARE | ▲ Buy | Grant | 5,345 | $0 | 6/18/2024 | View on chart |
| NMRA | ▲ Buy | Grant | 20,100 | $0 | 6/13/2024 | View on chart |
| ATRA | ▲ Buy | Grant | 150,000 | $0 | 3/31/2024 | View on chart |
| RARE | ▼ Sell | Open Market | 2,145 | $109K | 3/7/2024 | View on chart |
| RARE | ▼ Sell | Open Market | 2,550 | $130K | 3/7/2024 | View on chart |
| RARE | ▼ Sell | Open Market | 7,500 | $382K | 3/7/2024 | View on chart |
| RARE | ▲ Buy | Grant | 3,860 | $0 | 6/7/2023 | View on chart |
| RARE | ▼ Sell | Other | 3,300 | $171K | 6/7/2023 | View on chart |
| ATRA | ▲ Buy | Grant | 57,000 | $0 | 5/31/2023 | View on chart |
| RARE | ▲ Buy | Grant | 3,300 | $0 | 6/24/2022 | View on chart |
| ATRA | ▲ Buy | Grant | 20,500 | $0 | 6/23/2022 | View on chart |
| RARE | ▲ Buy | Option Exercise | 7,500 | $303K | 3/4/2022 | View on chart |
| ATRA | ▼ Sell | Open Market | 13,354 | $260K | 11/4/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Atara Biotherapeutics Resubmits Tabelecleucel BLA to FDA
Atara Biotherapeutics and its partner Pierre Fabre have filed a new biologics license application for the Tabelecleucel therapy with the U.S. FDA. The resubmission follows the earlier filing and reflects the companies' effort to move the product toward approval. The stock is currently near a long‑standing support level, which may be watched as the regulatory process continues.
Atara Biotherapeutics Resubmits Tabelecleucel BLA to FDA. Atara Biotherapeutics and its partner Pierre Fabre have filed a new biologics license application for the Tabelecleucel therapy with the U.S. FDA. The resubmission follows the earlier filing and reflects the companies' effort to move the product toward approval. The stock is currently near a long‑standing support level, which may be watched as the regulatory process continues.